Clinical Trial

XmAb20717 in Advanced Biliary Tract Cancers

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-arm, phase II clinical trial to evaluate the efficacy of XmAb20717 in patients with advanced biliary tract cancers who have progressed on, or were intolerant of, a gemcitabine-based chemotherapy regimen.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-03-17; most recent amendment 2025-09-11.
Status change: Recruiting → Active, Not Recruiting 2024-02-07
Status change: Not Yet Recruiting → Recruiting 2022-04-11
Trial Details
NCT Number NCT05297903
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: Xencor, Inc.
Conditions Biliary Tract Cancer
Enrollment 27 participants
Start Date 2022-04-11
Primary Completion 2026-12-02 (estimated)
Study Completion 2026-12-02 (estimated)
Updated on ClinicalTrials.gov 2025-09-15